tbuckley/cabot-search huggingface dataset:
Effect of surgical approach on node harvest in gastrectomy: Analysis of the National Cancer Database.
Authors: Michael David Watson, Sally J Trufan, Nicole Lee Gower, Joshua S. Hill, Jonathan C. Salo
Journal: Journal of Clinical Oncology (2019)

47 Background: Recent studies demonstrate significant surgical outcome advantages for patients undergoing minimally invasive versus open gastrectomy. Lymph node harvest at the time of gastrectomy is an indicator of adequate surgical resection and greater harvest is associated with improved staging and patient outcomes. Our aim is to evaluate lymph node harvest based on surgical approach. Our hypothesis is that a minimally invasive approach, particularly robot-assisted, will be associated with higher lymph node harvest. Methods: Patients undergoing gastrectomy for gastric adenocarcinoma in the period of 2010-2015 were identified using the National Cancer Database (NCDB). Data collected includes demographic data, institutional volume, approach, type of gastrectomy, tumor size, tumor location, pathologic T classification, year of diagnosis, Charlson-Deyo score and node harvest. Outcomes for patients undergoing open, laparoscopic, and robot-assisted gastrectomy were compared with univariate analysis and with a multivariate generalized linear mixed model (GLMM). Results: 19,555 patients were identified. There were 12,400 men (63.4%) and the mean age was 66.3 ± 12.5 years. 13,486 (69.0%) patients underwent open gastrectomy, 5,023 (25.7%) laparoscopic gastrectomy, and 1,046 (5.3%) robotic-assisted gastrectomy. Mean node harvest for open was 16.1 ± 11.5, laparoscopic was 15.1 ± 12.1, and robotic-assisted was 17.2 ± 13.3. Using a GLMM which controlled for the above listed covariates, robotic-assisted gastrectomy was associated with higher node harvest than both open (p = 0.041) and laparoscopic (p &lt; 0.001) while open was associated with higher node harvest than laparoscopic (p &lt; 0.001). There were 1582 operations with zero nodes harvested. In a sub-analysis of resections where at least one node was harvested (n = 17,973), the mean node harvest for open was 16.9 ± 11.1, laparoscopic was 17.5 ± 11.2, and robotic was 19.7 ± 12.3. Conclusions: This data suggests that a robot-assisted approach is associated with increased node harvest compared to laparoscopic and open approach in gastrectomy.
Abstract 12768: The Red Cell Distribution Width Standard Deviation (RDW-SD) More Strongly Predicts Mortality than the RDW
Authors: Joseph B Muhlestein, Jeffrey L Anderson, Brianna S Ronnow, Heidi T May, Benjamin D Horne
Journal: Circulation (2013)

Background: The red cell distribution width (RDW) predicts mortality, including among cardiovascular, pulmonary, trauma, and other patients, and in the general population. RDW is the standard devia...
First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes
Authors: Wojciech Jurczak, Simon Rule, William Townsend, David Tucker, Martin Dyroff, Barbara Sarholz, Jürgen Scheele, John G. Gribben, Pier Luigi Zinzani
Journal: Blood (2017)
Abstract 14155: Haemodynamic Changes After Aortic Valve Replacement in Bicuspid Aortic Valve Disease Differ With Prosthesis Type
Authors: Malenka M Bissell, Margaret Loudon, Victoria Stoll, Elizabeth Orchard, Stefan Neubauer, Saul G Myerson
Journal: Circulation (2015)

Introduction: Bicuspid aortic valve disease (BAV) is associated with dilatation of the proximal aorta and abnormal flow patterns, particularly increased helical flow and changes in the aortic wall shear stress. We assess the effect of different types of aortic valve replacement (AVR) on aortic flow patterns. Hypothesis: Aortic valve replacement in bicuspid aortic valve disease normalises ascending aortic flow patterns. Methods: We prospectively enrolled 87 participants: 27 BAV patients with prior AVR (10 mechanical, 8 bioprosthetic, 9 Ross procedure), 30 BAV patients with a native aortic valve and 30 healthy volunteers. All underwent 4D flow cardiovascular magnetic resonance. Results: The majority of patients with mechanical AVR or Ross showed a normalised flow pattern (70% and 67% respectively) with near normal rotational flow values (7.4±1.2 and 10.6±3.5 mm 2 /s respectively; normal range -5 to +11 mm 2 /s). They also showed reduced in-plane wall shear stress compared to native BAV (0.13±0.04 N/m 2 for mechanical AVR vs. 0.37±0.05 N/m 2 for native BAV, p&lt;0.05). In contrast, all subjects with bioprosthetic AVR showed abnormal flow patterns (mainly marked right-handed helical flow), with similar rotational flow values to native BAV (20.7±3.3 mm 2 /s and 25.9±3.1 mm 2 /s respectively, p&gt;0.05) and similar wall shear stress pattern. Data before and after AVR (n=16) supported these findings: mechanical AVR showed a significant reduction in rotational flow (29.3±5.3 to 7.9±1.2 mm 2 /s, p&lt;0.05) and in-plane wall shear stress (0.45±0.07 to 0.20±0.04 N/m 2 , p&lt;0.05), whereas these remained unchanged in the bioprosthetic AVR group. Conclusions: Abnormal flow patterns in BAV are significantly reduced after mechanical AVR or Ross procedure, but remain similar after bioprosthetic AVR. This is the first insight indicating that the type of valve replacement may influence post-operative aortic flow patterns, and could have important implications for future aortic growth.
Outcomes of stereotactic body radiotherapy for unresectable hepatocellular carcinoma.
Authors: Yizhou Zhao, Emma Dunne, Roy Ma, Mitchell Liu, Laura Beaton, Rosanna Yeung, Chad R. Lund, Devin Schellenberg
Journal: Journal of Clinical Oncology (2019)

401 Background: Stereotactic body radiotherapy (SBRT) is an emerging curative treatment for hepatocellular carcinoma (HCC). We report toxicity and efficacy of all patients treated in British Columbia, one of the largest series to date. Methods: From 2011 to Jan 2018, 99 patients underwent SBRT to 128 HCCs. Fiducials were placed and 4D CT (78.4%) and respiratory gating (19.6%) were used for motion management. Local control (LC), progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier. Cox regression identified outcome predictors. Results: Median Child-Pugh Score (CPS) was A5 (65% A5, 18% A6, 12% B7, 5% B8, 1% B9) and median Albumin-Bilirubin (ALBI) score was -2.55, grade 2 (48% gr1, 45% gr2, 6% gr3). Most (87.7%) had either Hepatitis B or C and 73.7% had prior HCC treatment, with 47.5% going on to further HCC treatment post SBRT and 42.4% deceased at the time of analysis. The median tumor size was 2.8 cm (range 0.8 – 11). The median prescribed biologically effective dose (BED 10 ) was 112.5 Gy, with 45 Gy in 3 fractions (BED 10 112.5 Gy) in 56.9% of cases and 45 Gy in 5 fractions (BED 10 85.5 Gy) in 30.4%. Median follow-up was 18.5 months (range 2.2 – 73.5). At 3 months, 12 (11.8%) patients had a rise in CPS of ≥ 2, and 26 (25.5%) patients had increased ALBI grade (median change in score of +0.16). Excluding laboratory findings, 14 (14.1%) patients developed CTCAE V5 grade 3 / 4 toxicities (ascites n = 12, hepatic failure n = 4, hepatic pain n = 1, nausea n = 1, GI bleed n = 1). The 1-, 2- and 3-year LC were 94.3%, 86.6% and 80.2%. The median PFS was 14.8 months, respectively 53.7%, 39.5% and 23.8% at 1, 2 and 3 years. The median OS was 41.1 months, respectively 80.3%, 63.5% and 55.2% at 1, 2 and 3 years. Univariate factors predicting improved LC were mean dose (Dmean) ≥ BED 10 100 Gy to GTV (p &lt; 0.01) and PTV (p = 0.03). Predictors of improved OS were prescription dose ≥ BED 10 100 Gy (p = 0.02), GTV Dmean ≥ BED 10 100 Gy (p &lt; 0.01), lower CPS (p = 0.04) and lower ALBI score pre-SBRT (p &lt; 0.01), smaller tumor size (p &lt; 0.01), no liver directed therapy post-SBRT (p &lt; 0.01), younger age (p = 0.03) and favorable ECOG (p = 0.01). Conclusions: SBRT achieves excellent LC, with low rates of toxicity and can be included with or without other therapies in HCC treatment.
Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development
Authors: Sarah C. Nabinger, Sisi Chen, Rui Gao, Chonghua Yao, Michihiro Kobayashi, Sasidhar Vemula, Aidan C. Fahey, Christine Wang, Cecil Daniels, H. Scott Boswell, George E. Sandusky, Lindsey D. Mayo, Reuben Kapur, Yan Liu
Journal: Leukemia (2019)
Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease
Authors: Yvonne Bausback, Tim Wittig, Andrej Schmidt, Thomas Zeller, Marc Bosiers, Patrick Peeters, Steffen Brucks, Aaron E. Lottes, Dierk Scheinert, Sabine Steiner
Journal: Journal of the American College of Cardiology (2019)

Randomized trials of drug-eluting stents (DES) and drug-coated balloons (DCB) for femoropopliteal interventions reported superior patency rates for both strategies compared to standard balloon angioplasty. To date, head-to-head comparisons are missing. The authors sought to compare DES versus DCB for femoropopliteal lesions through 36 months. Within a multicenter, randomized trial, 150 patients with symptomatic femoropopliteal disease were randomly assigned to primary DES implantation or DCB angioplasty with bailout stenting after stratification for lesion length (≤10 cm, >10 cm to ≤20 cm, and >20 cm to ≤30 cm). The primary effectiveness endpoint was primary patency at 12 months assessed by Kaplan-Meier. Secondary endpoints comprised major adverse events including death, major amputations, and clinically driven target lesion revascularization, and clinical outcomes. More than one-half of lesions were total occlusions, and the stenting rate was 25.3% in the DCB group. Kaplan-Meier estimates of primary patency were 79% and 80% for DES and DCB at 12 months (p = 0.96) but decreased to 54% and 38% through 36 months (p = 0.17), respectively. Freedom from clinically driven target lesion revascularization was >90% at 12 months but dropped to around 70% at 36 months in both groups. Overall, the mortality rate through 36 months was 7.3%, with 1 procedure-related death in the DCB group. Improvement of clinical outcomes was sustained through 36 months. Patency rates at 12 months suggest comparable effectiveness and safety of DES versus DCB plus bailout stenting in femoropopliteal interventions; a trend in favor of the DES was observed up to 36 months. (Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery [REAL PTX]; NCT01728441)
Colon Visualization on Bone Scan Due to Recto-abscess Fistula From Urinoma
Authors: Kang-Hung Chao, Tsung-Hsien Yen, Cheng-Kai Huang, Sheng-Pin Changlai
Journal: Clinical Nuclear Medicine (2019)

Abstract The accumulation of the bone-seeking agent in the bowel during a bone scan is rare. A 68-year-old man with colon cancer underwent bone scintigraphy for staging. Whole-body images revealed an abnormal accumulation of hot radioactivity in the abdominal cavity and the colon. Abdominal CT showed a recto-abscess fistula between the rectum and the urinoma. Incidental visualization of colonic radioactivity suggested the presence of a fistula between the bowel and the urinoma, explaining the peculiar finding of the bone-seeking agent in the bowel.
Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.
Authors: Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Jimmy J. Hwang, John Marshall, Ari M. Vanderwalde, Anthony Frank Shields, Heinz-Josef Lenz, Mohamed E. Salem, Philip Agop Philip, Richard M. Goldberg, W. Michael Korn, Sunnie S. Kim
Journal: Journal of Clinical Oncology (2019)

60 Background: DDR mutations are associated with higher neoantigen load and tumor infiltrating lymphocytes, and are a potential biomarker for immunotherapy. We investigated the association of DDR mutations in gastric (GC), esophageal (EC), and gastroesophageal junction (GEJ) cancers with MSI, PD-L1, and TMB, known predictors for immune checkpoint inhibitors. Methods: 20 DDR mutations were tested by Next-Generation Sequencing (NGS) with a 592-gene panel on a total of 1935 (709 EC; 831 GC; 355 GEJ) cancers. TMB was assessed by NGS, MSI by NGS or fragment analysis, and PD-L1 by IHC (22c3 for CPS or SP142). Results: GC had the highest DDR mutation rate compared to EC and GEJ (27% vs. 20%, p = 0.0005 and 17%, p = 0.0002, respectively). MSI-High (MSI-H) was significantly more common in the DDR mutated cohort (DDR-M) compared to non-mutated cancers (18% vs. 1%; p &lt; 0.0001). TMB-High (≥ 10 mutations/megabase [mt/MB]) was higher in DDR-M (35% vs. 21%; p &lt; 0.0001); in DDR-M cohort, GC had the highest TMB compared to DDR-M EC and GEJ (mean: 13.8 vs. 9.4 vs. 10 mt/MB, respectively; p &lt; 0.0001). DDR mutations were more frequent in the PD-L1 combined positive score (CPS) ≥ 50 group than CPS 0 (42.9% vs. 24%; p = 0.037) and CPS 1-9 (42.9% vs. 20.6%; p = 0.005). ARID1A, ATRX, BRCA2, and PTEN were the most prevalent DDR mutations in MSI-H (87%, 31%, 25%, 24%, respectively); ARID1A, ATRX, BRCA2, and PTEN in TMB-High (47%, 7.7%, 6.7%, 6.8%) and ARID1A, BRCA2, RAD50, and WRN in PD-L1 high (CPS ≥ 10) (48.5% vs. 5.2% vs. 2.5% vs. 3.4%). Conclusions: MSI-H, TMB-high and high PD-L1 expression were significantly more prevalent in the DDR-M cohort compared to non-DDR-mutated cancers, most pronounced in GC. Alterations in ARID1A, ATRX, BRCA2, and PTEN were correlated with MSI-H and TMB-high while ARID1A, BRCA2, RAD50, and WRN were correlated with increased PD-L1 expression. Our findings may help identify patients for tailored immunotherapy approaches in future clinical trials.
Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck—Reply
Authors: Karen L. Connolly, Kishwer S. Nehal, Erica H. Lee
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Effect of sex on group 2 innate lymphoid cells in the airways of mild and severe asthmatics
Authors: Michael Aw, Parameswaran Nair, Brittany Salter, Ruchong Chen, Kentaro Machida, Mark Inman, Paul M. O'Byrne, Gail M. Gauvreau, Roma Sehmi
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study
Authors: Jorne Lionel Biccler, Ingrid Glimelius, Sandra Eloranta, Knut B. Smeland, Peter de Nully Brown, Lasse Hjort Jakobsen, Henrik Frederiksen, Mats Jerkeman, Alexander Fosså, Therese M.L. Andersson, Harald Holte, Martin Bøgsted, Tarec Christoffer El-Galaly, Karin E. Smedby
Journal: Journal of Clinical Oncology (2019)

PURPOSE Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at different milestones during the follow-up. PATIENTS AND METHODS On the basis of a Nordic cohort of 2,582 patients diagnosed at ages 18 to 49 years between 2000 and 2013, 5-year relapse risks and 5-year restricted losses in expectation of lifetime were estimated for all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60) months. The median follow-up time was 9 years (range, 2.9 to 16.8 years). RESULTS The 5-year overall survival was 95% (95% CI, 94% to 96%). The 5-year risk of relapse was 13.4% (95% CI, 12.1% to 14.8%) overall but decreased to 4.2% (95% CI, 3.8% to 4.6%) given that patients reached EFS24. Relapse risk for patients treated with six to eight courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) was comparable to that of patients treated with six to eight courses of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) despite more adverse risk criteria among patients treated with BEACOPP. Both from diagnosis and if EFS24 was reached, the losses in expectation of lifetime during the following 5 years were small (from diagnosis, 45 days [95% CI, 35 to 54 days] and for patients who reached EFS24, 13 days [95% CI, 7 to 20 days]). In stage-stratified analyses of 5-year restricted loss in expectation of lifetime, patients with stages I to IIA disease had no noteworthy excess risk of death after they reached EFS24, whereas risk remained measurable for patients with stages IIB to IV cHL. CONCLUSION Real-world data on young patients with cHL from the Nordic countries show excellent outcomes. The outlook is particularly favorable for patients who reach EFS24, which supports limited relapse-oriented clinical follow-up.
Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience
Authors: Vasiliki Michalarea, Dima El-Sharkawi, Siraj Yusuf, Mary Gleeson, Laura Hickmott, Andrew Wotherspoon, Ayoma Attygalle, Simon O'Connor, Bhupinder Sharma, Yong Du, Imene Zerizer, Alan Horwich, Gillian Ross, Andrea Kuhnl, Sunil Iyengar, Ian Chau, David Cunningham
Journal: Blood (2018)
Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis
Authors: Carlos Fernandez de Larrea, David Moreno, Natalia Tovar, Maria Teresa Cibeira, Ignacio Isola, Laura Magnano, Laura Rosinol, Joan Bladé
Journal: Blood (2018)
RPS15 mutations Repress mRNA Translation in Chronic Lymphocytic Leukemia Cells
Authors: Stavroula Ntoufa, Stamatia Laidou, Fotis Psomopoulos, Marina Gerousi, Larry Mansouri, Georgios Tsiolas, Nikos Papakonstantinou, Achilles Anagnostopoulos, Niki Stavroyianni, Antonios M. Makris, Anastasia Hadzidimitriou, Richard Rosenquist, Kostas Stamatopoulos
Journal: Blood (2018)
The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity
Authors: David Digomann, Ina Kurth, Anna Tyutyunnykova, Oleg Chen, Steffen Löck, Ielizaveta Gorodetska, Claudia Peitzsch, Ira-Ida Skvortsova, Giulia Negro, Bertram Aschenbrenner, Graeme Eisenhofer, Susan Richter, Stephan Heiden, Joseph Porrmann, Barbara Klink, Christian Schwager, Adam A. Dowle, Linda Hein, Leoni A. Kunz-Schughart, Amir Abdollahi, Fabian Lohaus, Mechthild Krause, Michael Baumann, Annett Linge, Anna Dubrovska
Journal: Clinical Cancer Research (2019)

The heavy chain of the CD98 protein (CD98hc) is encoded by the SLC3A2 gene. Together with the light subunit LAT1, CD98hc constitutes a heterodimeric transmembrane amino acid transporter. High SLC3A2 mRNA expression levels are associated with poor prognosis in patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy. Little is known regarding the CD98hc protein-mediated molecular mechanisms of tumor radioresistance.CD98hc protein expression levels were correlated with corresponding tumor control dose 50 (TCD50) in HNSCC xenograft models. Expression levels of CD98hc and LAT1 in HNSCC cells were modulated by siRNA or CRISPR/Cas9 gene editing. HNSCC cell phenotypes were characterized by transcription profiling, plasma membrane proteomics, metabolic analysis, and signaling pathway activation. Expression levels of CD98hc and LAT1 proteins were examined by IHC analysis of tumor tissues from patients with locally advanced HNSCC treated with primary radiochemotherapy (RCTx). Primary endpoint was locoregional tumor control (LRC).High expression levels of CD98hc resulted in an increase in mTOR pathway activation, amino acid metabolism, and DNA repair as well as downregulation of oxidative stress and autophagy. High expression levels of CD98hc and LAT1 proteins were significantly correlated and associated with an increase in radioresistance in HNSCC in vitro and in vivo models. High expression of both proteins identified a poor prognosis subgroup in patients with locally advanced HNSCC after RCTx.We found that CD98hc-associated signaling mechanisms play a central role in the regulation of HNSCC radioresistance and may be a promising target for tumor radiosensitization.
Abstract 17963: Safety and Prognostic Impact of Starting Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker in Acute Phase of Hospitalization for Acute Heart Failure: Insights From REALITY-AHF
Authors: Kenji Yoshioka, Yuya Matsue, Takahiko Okumura, Keisuke Kida, Shogo Oishi, Satoshi Suzuki, Masayoshi Yamamoto, Takeshi Kitai, Shunsuke Kuroda, Akira Mizukami, Akihiko Matsumura
Journal: Circulation (2017)

Background: In hospitalized patients with acute heart failure (AHF), safety and prognostic impact of starting angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) in very acute phase has not been well elucidated. Methods: We utilized REALITY-AHF data in which 1682 patients hospitalized for AHF were registered. Patients not treated with ACEI/ARB at admission were eligible, and were divided into two groups: patients treated with ACEI/ARB (ACEI/ARB group) and without ACEI/ARB (non-ACEI/ARB group) within 48 hours of presentation to the hospital. Primary endpoint was a composite of 1-year mortality and hospitalization for AHF. Worsening renal function (WRF) (creatinine increase ≥0.3 mg/dL and ≥25% in 5 days) and length of hospital stay were also evaluated. Results: Among 900 AHF patients not treated with ACEI/ARB at admission, 288 patients were in ACEI/ARB group and 612 patients were in Non-ACEI/ARB group. There were no significant differences in the incidence of WRF (14.7 vs. ...
Diarrhea in an infant: food protein induced enterocolitis or very early onset inflammatory bowel disease
Authors: Cale Roberts, Curran H. Daigle, Katie Kennedy, Kathleen E. Sullivan, Judith R. Kelsen, Priya J. Patel, Antonella Cianferoni, Terri F. Brown-Whitehorn
Journal: Journal of Allergy and Clinical Immunology (2019)